{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:29:42Z","timestamp":1793773782740,"version":"4.6.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41375-020-0940-8","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T11:03:41Z","timestamp":1593255821000},"page":"2749-2753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. R.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. V.","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"S. K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Arendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Willrcih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,27]]},"reference":[{"key":"940_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540\u201355.","journal-title":"Nat Rev Cancer"},{"key":"940_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1006\/jsbi.2000.4248","volume":"130","author":"V Bellotti","year":"2000","unstructured":"Bellotti V, Mangione P, Merlini G. Review: immunoglobulin light chain amyloidosis-the archetype of structural and pathogenic variability. J Struct Biol. 2000;130:280\u20139.","journal-title":"J Struct Biol"},{"key":"940_CR3","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ajh.24772","volume":"92","author":"P Milani","year":"2017","unstructured":"Milani P, Murray DL, Barnidge DR, Kohlhagen MC, Mills JR, Merlini G, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017;92:772\u20139.","journal-title":"Am J Hematol"},{"key":"940_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41375-018-0194-x","volume":"33","author":"S Kumar","year":"2019","unstructured":"Kumar S, Murray D, Dasari S, Milani P, Barnidge D, Madden B, et al. Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients. Leukemia. 2019;33:254\u20137.","journal-title":"Leukemia"},{"key":"940_CR5","doi-asserted-by":"publisher","first-page":"E368","DOI":"10.1002\/ajh.25244","volume":"93","author":"T Kourelis","year":"2018","unstructured":"Kourelis T, Murray DL, Dasari S, Kumar S, Barnidge D, Madden B, et al. MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. Am J Hematol. 2018;93:E368\u201370.","journal-title":"Am J Hematol"},{"key":"940_CR6","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1182\/blood-2018-05-848986","volume":"132","author":"JR Mills","year":"2018","unstructured":"Mills JR, Kohlhagen MC, Willrich MAV, Kourelis T, Dispenzieri A, Murray DL. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood. 2018;132:670\u20132.","journal-title":"Blood"},{"key":"940_CR7","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","volume":"62","author":"JR Mills","year":"2016","unstructured":"Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA, et al. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016;62:1334\u201344.","journal-title":"Clin Chem"},{"key":"940_CR8","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362\u20139.","journal-title":"N Engl J Med"},{"key":"940_CR9","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","volume":"375","author":"A Dispenzieri","year":"2010","unstructured":"Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375:1721\u20138.","journal-title":"Lancet"},{"key":"940_CR10","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389\u2013430.","journal-title":"Stat Med"},{"key":"940_CR11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812\u20137.","journal-title":"Blood"},{"key":"940_CR12","doi-asserted-by":"publisher","unstructured":"Sidana S, Murray DL, Dasari S, Go R, Willrich MA, Snyder M, et al. Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease submitted. Am J Hematol. 2020. https:\/\/doi.org\/10.1002\/ajh.25843.","DOI":"10.1002\/ajh.25843"},{"key":"940_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0161-5890(86)90173-2","volume":"23","author":"FE Dwulet","year":"1986","unstructured":"Dwulet FE, O\u2019Connor TP, Benson MD. Polymorphism in a kappa I primary (AL) amyloid protein (BAN). Mol Immunol. 1986;23:73\u20138.","journal-title":"Mol Immunol"},{"key":"940_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1515\/bchm3.1985.366.2.617","volume":"366","author":"KG Toft","year":"1985","unstructured":"Toft KG, Sletten K, Husby G. The amino-acid sequence of the variable region of a carbohydrate-containing amyloid fibril protein EPS (immunoglobulin light chain, type lambda). Biol Chem Hoppe Seyler. 1985;366:617\u201325.","journal-title":"Biol Chem Hoppe Seyler"},{"key":"940_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/13506120009146835","volume":"7","author":"FJ Stevens","year":"2000","unstructured":"Stevens FJ. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid. 2000;7:200\u201311.","journal-title":"Amyloid"},{"key":"940_CR16","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1021\/acs.jproteome.5b00015","volume":"14","author":"S Dasari","year":"2015","unstructured":"Dasari S, Theis JD, Vrana JA, Meureta OM, Quint PS, Muppa P, et al. Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies. J Proteome Res. 2015;14:1957\u201367.","journal-title":"J Proteome Res"},{"key":"940_CR17","doi-asserted-by":"publisher","first-page":"14259","DOI":"10.1021\/bi7013773","volume":"46","author":"LH Connors","year":"2007","unstructured":"Connors LH, Jiang Y, Budnik M, Theberge R, Prokaeva T, Bodi KL, et al. Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains. Biochemistry. 2007;46:14259\u201371.","journal-title":"Biochemistry"},{"key":"940_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cellimm.2018.07.009","volume":"333","author":"I Gudelj","year":"2018","unstructured":"Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol. 2018;333:65\u201379.","journal-title":"Cell Immunol"},{"key":"940_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0080-9","volume":"8","author":"MA Gertz","year":"2018","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J. 2018;8:44.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0940-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0940-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0940-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:41:23Z","timestamp":1684618883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0940-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,27]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0940-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,27]]},"assertion":[{"value":"4 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DM and SD have intellectual property rights to the MASS-FIX assay and patents. The other authors have no conflicts related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}